^
Association details:
| Biomarker: | MYCN positive |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | dasatinib (Bcr-abl inhibitor, c-KIT inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + temozolomide (DNA synthesis inhibitor) + sirolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.
Published date:
05/25/2023
Excerpt:
RIST is the acronym for irinotecan and temozolomide (I/T) as backbone in combination with dasatinib (S) and rapamycin (R)...OS was significantly better in MYCN+ patients: 11 m vs 6.5 m in ITT (HR: 0.51 (95%-CI: 0.27, 0.96), p = 0.037) and 17 m vs 5 m in PP (HR: 0.34 (95%-CI: 0.14, 0.83), p = 0.018)….RIST was well tolerated and led to a significantly improved PFS and OS in MYCN+ patients, allowing a targeted approach for this high-risk population.
Secondary therapy:
irinotecan
DOI:
10.1200/JCO.2023.41.16_suppl.10001
Trial ID: